Monday, October 3, 2016

New Study on Frontier Pharma: Glioblastoma Multiforme - Cancer Immunotherapies Dominate First-in-Class Product Innovation


Glioblastoma multiforme (GBM) is a grade IV tumor that arises from astrocytes. It is the most common and aggressive human brain tumor, accounting for 15.4% of all primary brain tumors and 60-75% of all astrocytomas. It has a peak incidence between 55 and 84 years of age, with the median age of diagnosis being 64 years. To Get Sample Copy of Report visit @ http://www.researchmoz.us/enquiry.php?type=S&repid=826604
http://www.researchmoz.us/frontier-pharma-glioblastoma-multiforme-cancer-immunotherapies-dominate-firstinclass-product-innovation-report.html

No comments:

Post a Comment